VTYX 241220 0.50C (VTYX241220C500) Stock Options, News & Quotes

Account Info

Log Out

US OptionsDetailed Quotes

VTYX241220C500

Watchlist

0.00
0.000.00%

15min DelayClose Nov 25 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Ventyx Biosciences CEO Mohan Raju Buys $959,889 in Stock
Investing21:10 ET
Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) Latest 15% Decline Adds to One-year Losses, Institutional Investors May Consider Drastic Measures
Yahoo FinanceNov 17 08:07 ET
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
GlobeNewswireNov 12 07:30 ET
Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress
TipRanksNov 11 23:01 ET
Ventyx Biosciences Analyst Ratings
BenzingaNov 8 11:28 ET · Ratings
Oppenheimer Maintains Ventyx Biosciences(VTYX.US) With Buy Rating, Cuts Target Price to $9
Moomoo NewsNov 8 09:31 ET · Ratings

Comments

Jaguar8

Oct 15 08:03

NEWS

$Ventyx Biosciences (VTYX.US)$
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024
Ventyx Biosciences (Nasdaq: VTYX) presented new 52-week results from the Phase 2 trial of VTX002 (tamuzimod) in ulcerative colitis at UEG Week 2024. The late-breaking abstract highlighted high rates of clinical and endoscopic remission among long-term extension (LTE) completers at Week 52. CEO Raju Mohan emphasized the data's reinfo...

Jaguar8

Sep 23 12:35

Ventyx Biosciences Price Target Maintained With a $6.00/Share by HC Wainwright & Co

$Ventyx Biosciences (VTYX.US)$

Stock_Drift

Sep 23 08:00

9/23/24 👀’s on_watchlist. 🚨🚨*not financial advice*

$Nuvve (NVVE.US)$ $Treasure Global (TGL.US)$ $Expion360 (XPON.US)$ $Black Diamond Therapeutics (BDTX.US)$ $Ventyx Biosciences (VTYX.US)$
📊⚡️📊

Jaguar8

Sep 23 07:26

“Sanofi has agreed to make a $27 million strategic investment in the Company at an as-converted price of $3.8243 per share of common stock”

$Ventyx Biosciences (VTYX.US)$

Jaguar8

Sep 23 07:03

NEWS

$Ventyx Biosciences (VTYX.US)$
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX) ("Ventyx"), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Sanofi has agreed to make a $27 million strategic investment in the Company at an as-converted price...